XML 39 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of Stock-based Compensation Expense

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 (unaudited and in thousands):

 

   

Three Months Ended

March 31,

  
    2021     2020  
Cost of revenues   $ 22     $ 5  
Research and development     257       194  
General and administrative     778       634  
Sales and marketing     233       104  
Total stock-based compensation expense   $ 1,290     $ 937  
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

The assumptions that were used to calculate the grant date fair value of Oncocyte’s employee and non-employee stock option grants for the three months ended March 31, 2021 and 2020 were as follows (unaudited):

 

   

Three Months Ended

March 31,

  
    2021     2020  
Expected life (in years)     6.0       6.0  
Risk-free interest rates     1.02%       1.34%  
Volatility     102.62%       105.09%  
Dividend yield     -%       -%  
2010 Plan Activity [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):

 

Options  

Shares

Available

for Grant

    

Number

of Options

Outstanding

    

Weighted

Average Exercise Price

  
                   
Balance at December 31, 2020     -       1,218     $ 3.55  
Options exercised     -       (90)     $ 2.09  
Options forfeited, canceled and expired     -       -     $ -  
Balance at March 31, 2021     -       1,128     $ 3.65  
Exercisable at March 31, 2021             1,081     $ 3.76  
2018 Incentive Plan Activity [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise price):

 

   

Shares

Available

for Grant

    

Number

of Options

Outstanding

    

Number

of RSUs

Outstanding

    

Weighted

Average

Exercise Price

  
Balance at December 31, 2020     3,346       7,212       201     $ 2.60  
RSUs vested     -       -       -     $ -  
RSUs granted     -       -       -     $ -  
Options granted     (2,966)       2,966       -     $ 5.12  
Options exercised     -       (195)       -     $    
Options forfeited/cancelled     76       (76)       -     $ 2.69  
Balance at March 31, 2021     456       9,907       201     $ 3.35  
Options exercisable at March 31, 2021             2,849             $ 2.67